Ankyra Therapeutics has commenced dosing in its initial human trial phase, assessing the effectiveness of ANK-101, a novel anchored immunotherapy, targeting a range of solid cancers.
Novartis unveils fresh insights into Zolgensma's safety and performance, highlighting sustained and enhanced motor skills in SMA-affected children who are larger and older.
UK regulators have approved Ariceum Therapeutics to initiate an early-stage trial with its innovative I-123 tagged PARP blocker for individuals experiencing repeated glioblastoma.
Biocon Biologics, a fully owned arm of Biocon Ltd and a global player in biosimilars, announced today a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson.
FDA Grants ARTHEx Biotech Authorization to Start Early-Stage Clinical Study for ATX-01 in Treating Myotonic Dystrophy (DM1) under the ArthemiR™ Project.
Ironwood Pharma reveals encouraging initial findings from an international Phase III study of Apraglutide, a weekly treatment for Short Bowel Syndrome leading to Intestinal Failure in adults.